Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Foggia
Clinical trial register · Italy

Clinical Trials in Foggia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6791 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:19 UTC
6791
Studies in scope
all four open statuses
4079
Recruiting now
open to new participants
1019
Lead sponsors
across recruiting studies
Top sites
Milan 2846 Bologna 1303 Roma 1272 Naples 983 Rome 968
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca7 Novartis Pharmaceuticals7 University of Foggia6 Boehringer Ingelheim5 Amgen5
Site location
Milan2846 Bologna1303 Roma1272 Naples983 Rome968
All 489 locations
Target enrolment
to

Trials with a site in Foggia

95 of 6791 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Boehringer Ingelheim
Phase 3
466
Catania, Foggia, Forlì, Milan, Monza, Padova, Roma
2026-09-17
Not yet open
Core Strength Training, Anthropometry, and Postural Control in Youth Optimist Sailors
NCT07802782Postural Control, Athletic Performance, Physical Fitness, Core Stability
University of Foggia
Not applicable
40
Foggia
2026-09
Not yet open
GlaxoSmithKline
Phase 3
1,860
Bari, Foggia, Rome
2026-08-11
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Bari, Bologna, Foggia, Messina, Milan, Roma, Udine
2026-08-05
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Foggia, Forlì, Modena, Monza, Pavia, Rozzano, Siena, Torino
2026-06-11
Recruiting
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase 3
320
Catania, Foggia, Milan, Roma
2026-06-05
Not yet open
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2
144
Bari, Bologna, Meldola, Foggia, Florence, Genova, Province of Macerata, Milan
2026-06
Recruiting
ESTIM-UL: FES for Upper Limb Recovery After Stroke
NCT07513714Stroke, Post-Stroke Spasticity, Post-Stroke Hemiparesis
University of Foggia
Not applicable
40
Foggia
2026-05-01
Recruiting
AstraZeneca
Observational
200
Ancona, Bergamo, Foggia, Meldola, Milan, Modena, Naples, Padova
2026-04-16
Recruiting
Incyte Corporation
Phase 3
588
Bologna, Brescia, Candiolo, Foggia, Milan, Naples, Pisa, Roma
2026-04-09
Not yet open
Focal Vibration Therapy in Post-stroke Shoulder Pain
NCT07513753Stroke, Hemiplegic Shoulder Pain, Chronic Stroke Survivors
University of Foggia
Not applicable
60
Foggia
2026-04-01
Recruiting
University of Turin, Italy
Not applicable
820
Rozzano, Bologna, Florence, Foggia, Genova, Milan, Modena, Naples
2026-03-30
Recruiting
InRAD Observational Study
NCT07213700Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Non-Alzheimer Degenerative Dementia
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
Observational
50,000
Foggia, Milan
2026-03-30
Recruiting
Sanofi
Phase 3
160
Milan, Foggia, Roma
2026-01-14
Recruiting
Janssen Research & Development, LLC
Phase 3
258
Acireale, Cagliari, Florence, Foggia, Genova, Merano, Naples, Sassari
2026-01-08
Recruiting
Amgen
Phase 3
750
Foggia, Milan, Modena, Orbassano, Peschiera del Garda, Rozzano, Trento
2025-11-28
Active, closed
Hoffmann-La Roche
Phase 2
193
Foggia, Naples, Rome, Milan, Pozzilli
2025-11-13
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Ancona, Bergamo, Foggia, Pozzilli, Pavia, Roma, Gallarate, Naples
2025-11-11
Recruiting
Pfizer
Phase 2/3
982
Milan, Florence, Ancona, Foggia
2025-10-03
Recruiting
AllRock Bio, Inc.
Phase 2
40
Foggia, Pavia, Rome
2025-10-01
Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
300
Bologna, Foggia
2025-09-15
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Foggia, Milan, Naples, Padova, Palermo, Roma, Rozzano, Torino
2025-09-02
Recruiting
Novartis Pharmaceuticals
Observational
300
Alessandria, Asti, Bergamo, Brescia, Catania, Meldola, Cona, Foggia
2025-07-30
Active, closed
Vir Biotechnology, Inc.
Phase 3
150
Bergamo, Foggia, Milan, Pisa, Torino
2025-07-30
Recruiting
Amgen
Phase 3
12,800
Arzignano, Caserta, Ceccano, Chieti, Foggia, L’Aquila, Milan, Padova
2025-07-25
Recruiting
Bristol-Myers Squibb
Phase 3
586
Naples, Foggia, Roma
2025-07-21
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Bari, Bergamo, Brescia, Cortona AR, Foggia, Forlì, Milan, Naples
2025-06-25
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Bergamo, Foggia, Genova, Milan, Pavia, Roma
2025-06-23
Recruiting
GlaxoSmithKline
Phase 3
961
Castelvenere, Foggia, Roma, Catania, Ferrara, Genova, Rozzano
2025-06-23
Active, closed
Sanofi
Phase 3
1,092
Rome, Bari, Foggia, Lecce, Milan, Parma
2025-05-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Milan, Rozzano, Rome, Siena, Arezzo, Bergamo, Foggia, Terni
2025-05-13
Active, closed
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Not applicable
806
Foggia, Padova
2025-04-01
Recruiting
AstraZeneca
Phase 2
540
Catania, Foggia, Genoa, Roma
2025-03-26
Recruiting
AstraZeneca
Phase 3
11,300
Alessandria, Bari, Bergamo, Brescia, Chiavari, Cona, Foggia, Milan
2025-03-14
Active, closed
Hoffmann-La Roche
Phase 4
274
Foggia, Rome, Milan, Napoli, Torrette - Ancona
2025-03-14
Active, closed
Celgene
Phase 3
960
Milan, Orbassano, Rome, Padova, Arezzo, Foggia, Naples, Terni
2025-03-13
Recruiting
AstraZeneca
Phase 3
5,000
Bassano del Grappa, Bologna, Desio, Foggia, Genoa, Modena, Naples, Novara
2025-03-03
Recruiting
Landiolol in Mitral Valve Surgery
NCT06793670Cardiac Failure, Low Cardiac Output Syndrome
DrugLandiolol
Università Vita-Salute San Raffaele
Phase 4
1,500
Alessandria, Torino, Catania, Florence, Foggia, Genova, Milan, Palermo
2025-01-28
Active, closed
University of Foggia
Observational
30
Foggia
2025-01-21
Recruiting
Istituto Oncologico Veneto IRCCS
Not applicable
200
Bergamo, Bologna, Foggia, Padova, Palermo, Udine, Verona
2024-12-20
Recruiting
Università Vita-Salute San Raffaele
Not applicable
600
Catania, Foggia, Milan, Pisa
2024-12-20
Active, closed
Amgen
Phase 3
707
Foggia, Gallipoli, Genova, Milan, Orbassano, Trento
2024-12-09
Active, closed
Novartis Pharmaceuticals
Phase 4
24
Foggia
2024-11-25
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Bologna, Foggia, Milan, Modena, Palermo, Rome, Rozzano, Torino
2024-11-12
Recruiting
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Observational
600
Alessandria, Bari, Bologna, Brescia, Cagliari, Ferrara, Florence, Foggia
2024-11-04
Recruiting
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Observational
300
Bari, Bologna, Cagliari, Ferrara, Florence, Foggia, Genova, Messina
2024-11-04
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Foggia, Monza, Palermo, Pavia, Roma, Sassari, Ivrea, Trieste
2024-10-24
Recruiting
Pericardiotomy in Cardiac Surgery
NCT06486636Atrial Fibrillation, Atrial Flutter, Cardiac Events
Population Health Research Institute
Not applicable
1,400
Foggia
2024-10-21
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Bologna, Foggia, Milan, Modena, Novara, Palermo, Rome, Rozzano
2024-10-14
Recruiting
Prevention ICONA Dedicated Ensemble
NCT07186244PrEP, PrEP Adherence Monitoring, HIV, HIV -1 Infection
Fondazione ICONA
Observational
5,000
Chieti, Pescara, Bari, Foggia, Potenza, Caserta, Naples, Bologna
2024-09-09
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Foggia, San Giovanni Rotondo, Rozzano, Torino, Bologna, Catania, Messina, Milan
2024-09-04
Recruiting
Fondazione Don Carlo Gnocchi ETS
Not applicable
596
Acerenza, Bari, Bergamo, Catania, Catanzaro, Crotone, Foggia, Genova
2024-08-12
Recruiting
Amgen
Phase 3
450
Brescia, Castellana Grotte, Florence, Foggia, Genova, Meldola FC, Milan, Naples
2024-07-17
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Bergamo, Foggia, Genova, Naples, Pavia, Roma, Rozzano
2024-06-17
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Bergamo, Foggia, Milan, Novara, Palermo, Roma, Rome, Rozzano
2024-05-24
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Brescia, Catania, Florence, Foggia, Forlì, Milan, Modena, Monza
2024-05-06
Recruiting
CSL Behring
Phase 2/3
3,110
Bologna, Brescia, Cagliari, Caserta, Catania, Ferrara, Florence, Foggia
2024-04-27
Active, closed
Gilead Sciences
Phase 3
577
Brescia, Foggia, Milan, Monza, Pavia, Roma
2024-03-25
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Bergamo, Foggia, Milan, Modena, Naples, Novara, Palermo, Roma
2024-03-13
Recruiting
Meyer Children's Hospital IRCCS
Observational
90
Florence, Roma, Foggia, Palermo
2024-02-07
Recruiting
Genexine, Inc.
Phase 3
429
Brescia, Florence, Foggia, Genova, Pavia, Pisa, Verona
2024-01-25
Active, closed
Bioprojet
Phase 2
62
Bologna, Bosisio Parini, Cagliari, Calambrone, Foggia, Messina, Naples, Pavia
2023-12-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Meldola, Milan, Catania, Foggia, Terni
2023-12-18
Active, closed
Syndax Pharmaceuticals
Phase 2
145
Foggia, Milan, Monza, Torino, Padova, Siena, Catania, Florence
2023-12-11
Recruiting
Akero Therapeutics, Inc
Phase 3
1,650
San Giovanni Rotondo, Rozzano, Torino, Bologna, Foggia, Messina, Milan, Modena
2023-12-01
Active, closed
AstraZeneca
Phase 3
1,835
Bergamo, Bologna, Foggia, Genoa, Naples, Pisa, Roma, Torino
2023-11-07
Active, closed
Ipsen
Observational
1,057
Foggia, Lecco, Milan, Novara, Salerno, Verona
2023-11-01
Active, closed
Ad scientiam
Not applicable
336
Florence, Foggia, Milan
2023-09-22
Active, closed
Cytokinetics
Phase 3
500
San Donato Milanese, Brescia, Florence, Foggia, Milan, Naples, Pisa, Roma
2023-08-31
Active, closed
AstraZeneca
Phase 3
142
Castelfranco Veneto, Foggia, Palermo, Pisa, Rozzano
2023-08-16
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Bari, Foggia, Naples, Modena, Trieste, Pavia, Ranica
2023-07-06
Active, closed
University of Foggia
Phase 1
30
Foggia
2023-07-03
Recruiting
Platform of Randomized Adaptive Clinical Trials in Critical Illness
NCT05440851Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
University Health Network, Toronto
Not applicable
6,250
Cona, Foggia, Milan, Legnano, Palermo, Roma, Sassari, Trento
2023-04-30
Active, closed
Bayer
Phase 3
985
Foggia, Naples, Bologna, Modena, Reggio Emilia, Aviano, Rome, Genoa
2023-04-03
Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
1,000
Torrette, Castellana Grotte, Bologna, Catania, Foggia, Florence, Modena, Milan
2022-12-21
Recruiting
Montreal Heart Institute
Phase 3
10,000
Foggia, Acquaviva delle Fonti, Ferrara, Ravenna, Milan, Turin, Ancona, Florence
2022-12-21
Active, closed
Redx Pharma Ltd
Phase 2
48
Ancona, Catania, Foggia, Lecce, Milan, Modena, Roma, Verona
2022-09-08
Recruiting
UNICANCER
Phase 3
300
Bari, Candiolo, Foggia, Meldola, Milan, Naples, Roma, Rozzano
2022-04-19
Active, closed
University of Foggia
Not applicable
80
Foggia
2022-02-01
Recruiting
Azienda Ospedaliero-Universitaria Careggi
Observational
10,000
Bari, Bologna, Florence, Foggia, Genova, Messina, Milan, Naples
2022-01-10
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Brindisi, Foggia, Pozzilli, Messina, Modena, Pavia, Orbassano, Naples
2021-12-13
Active, closed
European Association of Urology Research Foundation
Observational
1,076
Bologna, Foggia, Parma
2021-11-19
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Catanzaro, San Giovanni Rotondo, Palermo, Bologna, Florence, Foggia, Milan, Roma
2021-04-01
Active, closed
Hoffmann-La Roche
Phase 3
746
Foggia, Naples, Parma, Rome, Bergamo, Milan, Mondovì (CN), Catania
2021-03-17
Recruiting
Centro Cardiologico Monzino
Observational
10,000
Milan, Ancona, Bari, Bergamo, Brescia, Foggia, Naples, Palermo
2021-02-10
Recruiting
SCAD : a Registry of Spontaneous Coronary Artery Dissection
NCT06601270Spontaneous Coronary Artery Dissection
European Society of Cardiology
Observational
1,500
Bergamo, Foggia, Genoa, Mantua, Milan, Monza
2021-01-30
Active, closed
IRCCS San Raffaele Roma
Not applicable
70
Bologna, Ferrara, Foggia, Messina, Roma, Rome, San Giovanni Rotondo
2020-12-28
Active, closed
Janssen Research & Development, LLC
Phase 3
518
Arezzo, Candiolo, Carpi, Catania, Foggia, Genova, Lugo, Milan
2020-12-07
Recruiting
Unity Health Toronto
Not applicable
740
Ferrara, Foggia, Rome
2020-11-23
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Udine, Brescia, Florence, Foggia, Meldola, Milan, Pavia, Ravenna
2020-09-16
Recruiting
Federico II University
Observational
5,000
Arzignano, Bari, Caserta, Catanzaro, Eboli, Foggia, Genova, Lecce
2020-03-07
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
Palermo, Foggia, Genova, Milan, Monza, Pavia, Roma
2019-09-23
Active, closed
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
DrugXeomin
Merz Pharmaceuticals GmbH
Phase 3
603
Foggia, Genova, Novara, Terracina
2019-09-16
Recruiting
Low INR to Minimize Bleeding With Mechanical Valves Trial
NCT03636295Bleeding Post-mechanical Valve Replacement, Thromboembolism Post-mechanical Valve Replacement
DrugWarfarin
Population Health Research Institute
Phase 3
2,625
Lecce, Alessandria, Ancona, Foggia
2019-09-05
Recruiting
Prof. Dr. med. Ingo Eitel
Observational
500
Foggia
2015-04
Rows per page Showing 1–95 of 95
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-italy/city/foggia

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,791 studies in total at the last sync on 11 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 95 of those studies with a site in Foggia.

How many clinical trials are recruiting in Foggia?

59 of the 95 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:19 UTC sync. A further 4 have not yet opened recruitment, 31 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Foggia), 95 studies
PhaseStudiesRecruitingShare
Phase 3482950.5%
Observational171417.9%
Not applicable14814.7%
Phase 2838.4%
Phase 4424.2%
Phase 2/3222.1%
Phase 1101.1%
Phase 1/2111.1%

Most active sponsors

Lead sponsors with the most studies (Foggia)
Lead sponsorStudiesRecruiting
AstraZeneca75
Novartis Pharmaceuticals74
University of Foggia61
Amgen54
Boehringer Ingelheim54
Hoffmann-La Roche30
Janssen Research & Development, LLC32
89bio, Inc.22
Akero Therapeutics, Inc22
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.